Breaking News Headlines Today

News from dermatologytimes.com

See all of dermatologytimes.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

Ground News has come across 355 headlines reported on by dermatologytimes.com during the past 3 months.

Ground News rates dermatologytimes.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

We’ve assigned a rating of Unknown factuality to dermatologytimes.com. You can read more about how we’ve determined dermatologytimes.com’s credibility and reliability as a news source here: https://ground.news/rating-system.

Information about dermatologytimes.com

Where is dermatologytimes.com located?dermatologytimes.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top dermatologytimes.com News

Health · United States

Breakthrough Male Birth Control Pill Passes Safety Test in Early Clinical Trial

75% Center coverage: 12 sources

A hormone-free male birth control pill passed its first safety test in ongoing clinical trials, marking a major milestone in its development.The results from the early phase 1 clinical trial testing the safety of the daily pill referred to as YCT-529 were published on Tuesday in the journal Communications Medicine.The pill is designed to decrease sperm count by impairing retinoic acid signaling in the testes, according to its San Francisco-based…See the Story

FDA · United States

FDA Rejects RP1 for Advanced Melanoma, Says IGNYTE Not a ‘Well-Controlled’ Trial

67% Center coverage: 3 sources

The FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license application for vusolimogene oderparepvec in combination with nivolumab for the treatment of advanced melanoma.According to a company press release, the letter indicates that the FDA cannot approve the application for vusolimogene oderparepvec (RP1) — the company’s lead See the Story

AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

100% Center coverage: 1 sources

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients...See the Story

News from dermatologytimes.com